Ototoxicity

Ototoxicity is damage to the inner ear caused by certain drugs or chemicals, which can produce hearing loss, ringing in the ears (tinnitus), or problems with balance. The injury can affect the cochlea (hearing), the vestibular system (balance), or both, and may be temporary or permanent depending on the agent and the cumulative dose received.

Origin

The word combines the Greek otos (ear) with toxikon (poison). It came into common medical use in the mid-twentieth century as aminoglycoside antibiotics and later platinum-based chemotherapy drugs were recognized to damage inner-ear structures.

Significance in Asbestos Context

Ototoxicity matters to mesothelioma and asbestos-related lung cancer patients because cisplatin, a cornerstone of standard chemotherapy regimens (typically paired with pemetrexed), is one of the most ototoxic drugs in clinical use. Carboplatin, sometimes substituted when cisplatin is not tolerated, carries a lower but still real risk. Hearing loss and tinnitus from treatment are real, often permanent harms that affect daily life, communication with family, and the ability to participate in medical decisions, and they are compensable as part of the damages in an asbestos claim or trust filing. Because defendants may try to blame age-related hearing loss or prior noise exposure, a baseline audiogram before chemotherapy begins is the single most important step for documenting that the loss came from treatment of an asbestos-caused disease. Audiograms before, during, and after chemotherapy, along with records of cumulative cisplatin dosing, form the medical foundation your legal team will use to include this harm in the case.

Example Sentence

After several cycles of cisplatin and pemetrexed for pleural mesothelioma, the patient developed high-frequency hearing loss and persistent tinnitus consistent with ototoxicity, which his attorney included in the damages portion of his claim.

Related Terms

Cisplatin, Carboplatin, Pemetrexed, Audiometry, Sensorineural Hearing Loss, Tinnitus, Quality of Life Damages

Notes

• Before starting cisplatin or carboplatin, ask your oncologist for a referral for a baseline audiogram. Request follow-up audiograms during treatment and at the end of therapy. This creates the medical record that ties any hearing loss to chemotherapy rather than to aging or prior noise exposure.
• Report new symptoms (muffled hearing, trouble following conversations in noisy rooms, new ringing or buzzing, dizziness, or imbalance) to your oncology team promptly. Dose adjustments, a switch from cisplatin to carboplatin, or other protective measures may be available if caught early.
• Keep copies of every audiogram, the chemotherapy administration record showing cumulative cisplatin dose (measured in mg/m²), and any referrals to audiology or ENT. These records are used both for clinical follow-up and for documenting damages in trust claims, VA claims, and civil suits.
• If hearing loss develops, ask about hearing aids, assistive listening devices, and audiology rehabilitation; the cost of these devices and ongoing care should be included in your damages calculation.
• Family members should know that untreated hearing loss can lead to isolation and depression and can interfere with the patient's ability to follow medical discussions. Bringing a family member to appointments and using written summaries can help.